XNAS
TRNS
Market cap817mUSD
Aug 24, Last price
87.38USD
1D
-5.54%
1Q
14.30%
Jan 2017
709.07%
Name
Transcat Inc
Chart & performance
P/E
152.13
P/S
2.46
EPS
0.57
Div yield, %
—
Shrs. gr., 5y
4.07%
Rev. gr., 5y
7.56%
Revenues
332m
+19.20%
Net income
5m
-62.96%
CFO
35m
-10.61%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2024‑03 | 2023‑03 | 2023‑03 | 2022‑03 | 2022‑03 | 2021‑03 | 2021‑03 | 2020‑03 | 2020‑03 | 2019‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2017‑03 | |
| Income | |||||||||||||||||
Revenues | |||||||||||||||||
Cost of revenue | |||||||||||||||||
Unusual Expense (Income) | |||||||||||||||||
NOPBT | |||||||||||||||||
NOPBT Margin | |||||||||||||||||
Operating Taxes | |||||||||||||||||
Tax Rate | |||||||||||||||||
NOPAT | |||||||||||||||||
Net income | |||||||||||||||||
Dividends | |||||||||||||||||
Dividend yield | |||||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||||
BB yield | |||||||||||||||||
| Debt | |||||||||||||||||
Debt current | |||||||||||||||||
Long-term debt | |||||||||||||||||
Deferred revenue | |||||||||||||||||
Other long-term liabilities | |||||||||||||||||
Net debt | |||||||||||||||||
| Cash flow | |||||||||||||||||
Cash from operating activities | |||||||||||||||||
CAPEX | |||||||||||||||||
Cash from investing activities | |||||||||||||||||
Cash from financing activities | |||||||||||||||||
FCF | |||||||||||||||||
| Balance | |||||||||||||||||
Cash | |||||||||||||||||
Long term investments | |||||||||||||||||
Excess cash | |||||||||||||||||
Stockholders' equity | |||||||||||||||||
Invested Capital | |||||||||||||||||
ROIC | |||||||||||||||||
ROCE | |||||||||||||||||
| EV | |||||||||||||||||
Common stock shares outstanding | |||||||||||||||||
Price | |||||||||||||||||
Market cap | |||||||||||||||||
EV | |||||||||||||||||
EBITDA | |||||||||||||||||
EV/EBITDA | |||||||||||||||||
Interest | |||||||||||||||||
Interest/NOPBT | |||||||||||||||||